The drug developed by Texas A&M and University of Texas MD Anderson Cancer Center scientists could be an effective treatment for COVID-19 and other illnesses.
There’s a new drug in development that could prevent the next global pandemic. Researchers at the Texas A&M University Health Science Center (Texas A&M Health) and University of Texas MD Anderson Cancer Center are testing PUL-042, an inhaled therapeutic that provides broad protection against a range of life-threatening respiratory infections.
Results from a recent phase 2 clinical trial conducted through Houston-based biotechnology company Pulmotect, Inc. showed that it may be an effective treatment for COVID-19 and other respiratory illnesses. Patients in the trial treated with inhaled PUL-042 showed improvement in cough and shortness of breath more quickly than those who received a placebo treatment. They also experienced fewer hospitalizations and intensive care admissions.
Inhaled PUL-042 stimulates the lungs’ innate immune system, protecting against a wide variety of respiratory pathogens. The scientists behind it think PUL-042 could be directed against all existing and future variants of the COVID-19 virus, as well as future pandemics. Based on the promising results from this trial and remarkable activity in pre-clinical models, PUL-042 also has potential for use in other patient populations.
“We have not found a virus PUL-042 cannot work against in the lungs, in animal studies,” said Dr. Colin Broom, CEO of Pulmotect. “As an easily administered inhaled therapy, PUL-042 could have value in reducing the impact of COVID-19 irrespective of the development of further variants. It also has potential utility for other patient populations which we plan to explore, including immunosuppressed cancer patient.”
The innate immune system is the body’s first line of defense against invading pathogens. When germs and foreign substances enter the body, the innate immune system responds quickly to fight them off. PUL-042, the first drug in its class, is composed of two small synthetic molecules and works by stimulating specific innate immune receptors in the lung lining within minutes. Protection only lasts for about three to five days, but it can be repeatedly administered once every few days.
PUL-042 was discovered by Magnus H??k, regents and distinguished professor at the Texas A&M Health Institute of Biosciences and Technology, and Dr. Burton Dickey, chair of the pulmonary department at MD Anderson Cancer Center.
“The lungs are the point of entry for many viruses and bacteria. By activating the innate immune defense of the lungs, PUL-042 can provide effective protection against a wide range of deadly pathogens,” H??k said. “We believe that if we had this therapy available in December of 2019, we could have prevented the COVID-19 pandemic and avoided the 6 million lives lost.”
The Food and Drug Administration approved Pulmotect to begin two human clinical trials of PUL-042 last year, one focused on protection and another on treatment for COVID-19. Funding support for the trials was provided by the U.S. Department of Defense.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Kansas man arrested after 2 fatal shootings, police chase
A 51-year-old Kansas man was arrested Sunday morning in connection with two fatal overnight shootings in Lawrence after fleeing from police and firing on officers during the chase. Lawrence Police ...
- Clemson's Thomas Austin a new-school coach for Tigers' offensive line
From a "safe seat" to paintball trips, new Clemson offensive line coach Thomas Austin stands out for his ability to connect with players. Will he be able to take Clemson's ...
- Pct. 8 deputy constable at home resting after being rescued by tow truck driver
Once he arrived at the scene, Precinct 8 said Borgstrom was able to break the driver-side window and pull LeMelle out before the flames reached the cabin. "I would like to extend my thanks to Mr ...
- Show Your 2022 NASCAR Cup Series Love
The following article is an associate of Okanjo, an affiliate marketing agency that helps us monetize our content. Products sold through the links in the article allow us to receive ...
- Neighbors push for stop signs on Via Las Cumbres near Tecolote Canyon
SAN DIEGO — Neighbors in one Tecolote Canyon neighborhood are pushing for stop signs and speed bumps on a street they say is extremely dangerous. “It’s a blind intersection, so if we want to ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Incannex Healthcare partners with R&D organisation Curia to scale-up manufacture of drug targeting traumatic brain injury
"Its manufacture will facilitate investigation of the product in the well-controlled clinical trials we are designing, with feedback ...
- Incannex Engages Curia to scale-up manufacture of inhaled drug product to treat traumatic brain injury
Incannex (ASX:IHL) advances its inhaled drug product for treatment of traumatic brain injury, with a new development and manufacturing deal.
- Liquidia Announces the Publication of Long-Term Clinical Data from Completed INSPIRE Study in the Journal Pulmonary Circulation
Evaluated doses of YUTREPIA™ (treprostinil) inhalation powder from 26.5 mcg to 212 mcg which are comparable to 3 to 24 breaths of nebulized Tyvaso® per sessionAchieved therapeutic levels by Month 2 an ...
- MannKind Corporation to Participate in the BTIG Biotechnology Conference
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today ...
- Therapeutic Effects of Inhaled Inactivated Mycobacterium Phlei in Adult Patients With Moderate Persistent Asthma
and increases FEV1-PD20 in patients with moderate persistent asthma. Inhaled immunotherapy has a therapeutic effect for asthma.